Skip to Content

NovaBay Pharmaceuticals Inc NBY

Morningstar Rating
$0.09 0.00 (0.89%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

NBY is trading at a 55% discount.
Price
$0.09
Fair Value
$6.95
Uncertainty
Extreme
1-Star Price
$3.51
5-Star Price
$3.96
Economic Moat
Gxwg
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NBY is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.09
Day Range
$0.080.09
52-Week Range
$0.081.95
Bid/Ask
$0.09 / $0.09
Market Cap
$2.72 Mil
Volume/Avg
691,280 / 2.3 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
0.03
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically eyecare and skincare products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. It has two reportable segments: Eyecare and Wound Care and Skincare.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
26

Valuation

Metric
NBY
Price/Earnings (Normalized)
Price/Book Value
0.75
Price/Sales
0.03
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
NBY
Quick Ratio
0.91
Current Ratio
1.67
Interest Coverage
Quick Ratio
NBY

Profitability

Metric
NBY
Return on Assets (Normalized)
−51.12%
Return on Equity (Normalized)
−134.02%
Return on Invested Capital (Normalized)
−69.06%
Return on Assets
NBY
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRRrmtslwtjfMrxm$564.6 Bil
REGN
Regeneron Pharmaceuticals IncFzftymzVbchnkb$102.8 Bil
VRTX
Vertex Pharmaceuticals IncHlgkzrbbzZtlnk$102.5 Bil
MRNA
Moderna IncClvjzrlvfXbc$41.0 Bil
ARGX
argenx SE ADRZhkmwpmlNhdl$22.8 Bil
BNTX
BioNTech SE ADRPltptzzzVfsbw$21.7 Bil
ALNY
Alnylam Pharmaceuticals IncNccgwnffSdcrks$18.8 Bil
BMRN
Biomarin Pharmaceutical IncWmzqtmkxMpcykqv$17.4 Bil
RPRX
Royalty Pharma PLC Class ANrbcsqwzqKhzzt$12.6 Bil
INCY
Incyte CorpBftlmyqbKhvbny$12.1 Bil

Sponsor Center